Physician profile
Steven Mark Ramsaran
NPI 1538134416
$2,676.67
in general payments reported to CMS, 2019-2025
21 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $223 · 2021: $478 · 2022: $513 · 2023: $457 · 2024: $397 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.02 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $407.38 | 2020-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $368.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.59 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $230.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $165.45 | 2019-2025 | |
| Mylan Specialty L.P. | $143.69 | 2020-2024 | Yupelri |
| Abbvie INC. | $79.85 | 2021-2024 | |
| Pfizer INC. | $73.65 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $68.26 | 2019-2021 | |
| Glaxosmithkline, LLC. | $55.22 | 2021 | |
| Neurocrine Biosciences, INC. | $33.27 | 2022-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $32.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.42 | 2019 | |
| Amarin Pharma, INC. | $30.52 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.68 | 2023 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $22.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.76 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2021 | |
| Viatris Specialty LLC | $14.00 | 2025 | Yupelri |
| Genzyme Corporation | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ramsaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.